**Author details**

Lee Roy Morgan1 , Andrew H. Rodgers1 , Gerard Bastian4 , Edmund Benes1 , William S. Waud6 , Christopher Papagiannis7 , Dan Krietlow7 , Branko S. Jursic2 , Robert F. Struck5 , Gerald LaHoste3 , Melissa Thornton1 , Melody Luttrell1 , Edward Stevens2 and Rodger Thompson8

[7] O'Reilly S, Grochow L, Donehower RC, Bowling K, Chen TL, Hartman N, Struck R, Rowinsky EK. Phase I and pharmacologic studies of penclomedine, a novel alkylat‐

[8] Jodrell DI, Bowman A, Stewart M, Dunlop N, French R, MacLellan A, Cummings J, Smyth JF. Dose-limiting neurotoxicity in a phase I study of penclomedine (NSC 388720, CRC 88-04), a synthetic alpha-picoline derivative, administered intravenous‐

[9] Berlin J, Wahamaki A, Tutsch KD, Alberti D, Feierabend C, Binger, K, Arzoomanian, RZ, Volkman, J, Karca J, Mornocha, R, Stewart J, Wilding G. Phase I, pharmacokinet‐ ic and bioavailability study of oral penclomedine administered daily x 5 every four

[10] O'Reilly S, O'Hearn E, Rowinsky EK, Struck RF, Molliver ME. Neuroanatomic stud‐ ies of the cerebellar effects of penclomedine. Proc. Amer. Assoc. Cancer Res, 37:

[12] O'Reilly S, O' Hearn E, Struck RF, Rowinsky EK, Molliver ME. The alkylating agent penclomedine induces degeneration of purkinje cells in the rat cerebellum. Invest

[13] Morgan LR, Struck RF, Waud W, Jursic BS, Serota DG, Papagiannis C, Rodgers AH, Thornton, ME, GS LaHoste. Comparative pharmacokinetics and intermediary metab‐ olism of 4-demethyl-4-cholesteryl-oxycarbonylpenclomedine (DM-CHOC-PEN),

[14] Pletsas D, Wheelhouse RT, Pletsa V, Nicolaou A, Jenkins TC, Bibby MC. Kytopoulas

[15] Morris, R. Development of water-maze procedure for studying spatial learning in the

[16] Saab, BJ, Saab, AMP, Roder, JC. Statistical and theoretical considerations for the plat‐

[17] Weiner RS, Friedlander P, Gordon C, Mahmood T, Ware ML, Bastian G, Rodgers AH, Urien S, Morgan, LR. A first-in-humans: phase I clinical for 4-Demethyl-4-cho‐ lesteryl-oxycarbonylpenclomedine (DM-CHOC-PEN). Proc Amer. Assoc. Cancer

[18] Dietrich J, Han R, Yang Y, Mayer-Proschel M, Noble M. CNS progenitor cells and oli‐ godendrocytes are targets of chemotherapeutics *in vitro* and *in vivo*. J Biol. 5:22-32,

form re-location water maze. J. Neurosci. Meth. 198:44-52, 2011.

nine-DNA alkyltransferase: implications for the design of DNA-modifying drugs.

derivatives resistant to repair by O6

Comparative Preclinical Pharmacology and Toxicology for…

http://dx.doi.org/10.5772/58353

261


ing agent in patients with solid tumors. J Clin Oncol, 15: 1974-1984, 1997.

ly. Brit J Cancer, 77: 808-811, 1998.

[11] 374-375, 1996.

New Drugs, 21:269, 2003.

weeks. Proc. Amer. Assoc. Cancer Res, 40: 92, 1999.

EORTC/ AACR/NCI (Berlin), Abst 871, 2010.

rat. J. Neuroscience Methods, 11: 47-60, 1984.

SA. Polar, functionalized guanine-O6

Eur. J. Med Chem., 11: 1-10, 2006.

Res., 54, 1173, 2013.

2006.


5 Cancermedica, LLC, Birmingham, AL, USA

